HGF
Increase · moderate
c-Met/HGF agonism
Literature evidence
Vivy evidence dossier
Also indexed as Dihexa, P-631, Angiotensin IV analog
Evidence labels describe the material available in this reference entry. They do not establish that a compound is appropriate, effective, or safe for you. Inclusion is not a recommendation to use it.
Reference context
This field summarizes the library record. Half-life can vary with formulation, indication, and individual clinical context.
Observed relationships
Increase · moderate
c-Met/HGF agonism
Literature evidence
Increase · moderate
Promotes synaptogenesis
Literature evidence
Increase · small
Neurotrophic signaling
Literature evidence
Increase · moderate
Supports memory formation
Literature evidence
Decrease · small
Neuroprotective antioxidant effects
Literature evidence
Decrease · small
Anti-inflammatory signaling
Literature evidence
Decrease · small
Cytokine modulation
Literature evidence
Decrease · moderate
Reduces inflammatory glial signaling
Literature evidence
Increase · small
Neurotrophic support
Literature evidence
Increase · moderate
Supports synaptic remodeling
Literature evidence
Increase · small
Neurotransmitter support
Literature evidence
Increase · small
Cholinergic signaling
Literature evidence
Increase · small
Improves memory formation
Literature evidence
Decrease · small
Improves processing speed
Literature evidence
Decrease · small
Neurotrophic effects
Literature evidence
Increase · moderate
Enhances synapse formation
Literature evidence
Keep in view
Dihexa is a synthetic peptide derivative of angiotensin IV that has shown neuroregenerative and cognitive-enhancing effects in preclinical studies. Not FDA-approved.
Keep the reference close
Hey Vivy helps you organize protocols and review change over time. It does not diagnose, prescribe, or replace qualified care.